初产妇母体血清胎盘蛋白水平与不良妊娠结局相关
基于Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be队列的巢式病例对照研究,检测妊娠早期和中期9种胎盘蛋白,发现其水平与早产、子痫前期、小于胎龄儿和死产存在关联,但单独或联合临床特征预测不良妊娠结局的ROC曲线下面积仍较低(0.65-0.78),不支持作为临床生物标志物。
要点
- 初产妇孕6-13周和16-21周母血清9种胎盘蛋白水平与不良妊娠结局存在显著关联。
- 各分析物单独预测不良妊娠结局的ROC曲线下面积较低(0.50-0.64)。
- 联合临床特征和多种分析物后ROC曲线下面积仍较低(0.65-0.78),不支持临床用作预测标志物。
核心结论
- 初产妇孕早期母血清分析物水平与后续不良妊娠结局存在显著关联。
- 这些分析物的检测特征不支持其单独或联合母体临床特征作为预测不良妊娠结局的临床生物标志物。
研究设计与样本
- 基于Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be队列的巢式病例对照研究,共纳入10,038例符合条件的初产妇。
- 比较800例早产(466例自发性早产、330例医学指征早产、4例未分类早产)、568例子痫前期、406例小于胎龄儿、49例死产与911例无并发症足月分娩对照。
- 于孕6-13周和16-21周两次采集母血清,检测9种分析物:血管内皮生长因子、胎盘生长因子、内皮糖蛋白、可溶性fms样酪氨酸激酶-1、含解整合素和金属蛋白酶域蛋白12、妊娠相关血浆蛋白A、游离β-人绒毛膜促性腺激素、抑制素A和甲胎蛋白。
- 主要结局为孕20 0/7至36 6/7周早产;次要结局为自发性早产、医学指征早产、子痫前期、小于胎龄儿和死产。
主要发现
- 各分析物水平在病例与对照之间于1次或2次访视时通常存在差异,但所有比较中比值比显示病例与对照差异小于2倍。
- 各分析物预测早产及其他不良妊娠结局的ROC曲线下面积相对较低(范围0.50-0.64)。
- 逻辑回归模型显示,基线临床特征联合分析物组合预测不良妊娠结局的ROC曲线下面积大于单独基线特征,但各结局的ROC曲线下面积仍相对较低(范围0.65-0.78)。
临床怎么用
- 原文结论指出这些分析物的检测特征不支持其作为临床生物标志物用于预测不良妊娠结局,无论单独使用还是联合母体临床特征。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Eunice Kennedy Shriver National Institute of Child Health and Human Development Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be was established to investigate the underlying causes and pathophysiological pathways associated with adverse pregnancy outcomes in nulliparous gravidas. OBJECTIVE: This study aimed to study placental physiology and identify novel biomarkers concerning adverse pregnancy outcomes, including preterm birth (medically indicated and spontaneous), preeclampsia, small-for-gestational-age neonates, and stillbirth. We measured levels of placental proteins in the maternal circulation in the first 2 trimesters of pregnancy. STUDY DESIGN: Maternal serum samples were collected at 2 study visits (6-13 weeks and 16-21 weeks), and levels of 9 analytes were measured. The analytes we measured were vascular endothelial growth factor, placental growth factor, endoglin, soluble fms-like tyrosine kinase-1, A disintegrin and metalloproteinase domain-containing protein 12, pregnancy-associated plasma protein A, free beta-human chorionic gonadotropin, inhibin A, and alpha-fetoprotein. The primary outcome was preterm birth between 20 0/7 and 36 6/7 weeks of gestation. The secondary outcomes were spontaneous preterm births, medically indicated preterm births, preeclampsia, small-for-gestational-age neonates, and stillbirth. RESULTS: A total of 10,038 eligible gravidas were enrolled in the Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be cohort, from which a nested case-control study was performed comparing 800 cases with preterm birth (466 spontaneous preterm births, 330 medically indicated preterm births, and 4 unclassified preterm births), 568 with preeclampsia, 406 with small-for-gestational-age birth, and 49 with stillbirth with 911 controls who delivered at term without complications. Although levels of each analyte generally differed between cases and controls at 1 or 2 visits, the odds ratios revealed a <2-fold difference between cases and controls in all comparisons. Receiver operating characteristic curves, generated to determine the relationship between analyte levels and preterm birth and the other adverse pregnancy outcomes, resulted in areas under the receiver operating characteristic curves that were relatively low (range, 0.50-0.64) for each analyte. Logistic regression modeling demonstrated that areas under the receiver operating characteristic curves for predicting adverse pregnancy outcomes were greater using baseline clinical characteristics and combinations of analytes than baseline characteristics alone, but areas under the receiver operating characteristic curves remained relatively low for each outcome (range, 0.65-0.78). CONCLUSION: We have found significant associations between maternal serum levels of analytes evaluated early in pregnancy and subsequent adverse pregnancy outcomes in nulliparous gravidas. However, the test characteristics for these analytes do not support their use as clinical biomarkers to predict adverse pregnancy outcomes, either alone or in combination with maternal clinical characteristics.
引用
- Parry S, Carper BA, Grobman WA, et al. Placental protein levels in maternal serum are associated with adverse pregnancy outcomes in nulliparous patients. Am J Obstet Gynecol. 2022. PMID: 35487327. doi:10.1016/j.ajog.2022.03.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。